The conventional wisdom that we need to reduce spending on prescription drugs is all wrong. In an ideal health care system, we’d spend more on drugs, not less.
While the pace of startup formation in biotech has been accelerating over the past decade, early signs suggest the malaise in the markets is finding its way back into the venture creation ecosystem.
Over my many years in the biopharma industry, working across disease areas, including orphan indications, I have learned that to impact patients’ lives credibly and meaningfully, we must raise awareness about the conditions we are attempting to treat. One of the most effective ways is to engage with patient advocacy groups who are more closely connected to patients and caregivers and have a deep knowledge of their needs. Access to patient groups is particularly important for work related to rare disease indications given the challenging combination of urgent patient needs, and limited resources and knowledge.
By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC.
There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market.
Misery loves company, and so it goes with the stock market for the innovation ecosystem these days.